Phase II Trial to Evaluate The Efficacy of Obinutuzumab (RO5072759) + Bendamustine Treatment in Patients With Refractory Or Relapsed Chronic Lymphocytic Leukemia

Trial Profile

Phase II Trial to Evaluate The Efficacy of Obinutuzumab (RO5072759) + Bendamustine Treatment in Patients With Refractory Or Relapsed Chronic Lymphocytic Leukemia

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Obinutuzumab (Primary) ; Bendamustine
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 14 Jun 2017 Planned End Date changed from 1 Oct 2018 to 19 Nov 2018.
    • 14 Jun 2017 Planned primary completion date changed from 1 Oct 2018 to 19 Nov 2018.
    • 03 Oct 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top